{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:48:13Z","timestamp":1767142093737,"version":"build-2238731810"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"SBAVP","award":["SBAVP-RG\/Ph.D\/21"],"award-info":[{"award-number":["SBAVP-RG\/Ph.D\/21"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12020-020-02472-5","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T12:03:58Z","timestamp":1599480238000},"page":"76-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus"],"prefix":"10.1007","volume":"71","author":[{"given":"Sriram","family":"Naresh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna R.","family":"Bitla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. V. L. N. Srinivasa","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Sachan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadagiri Lakshmi","family":"Amancharla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"issue":"25 Pt B","key":"2472_CR1","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"N.J. Stone, J.G. Robinson, A.H. Lichtenstein et al. American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63(25 Pt B), 2889\u20132934 (2014)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"2472_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","volume":"106","author":"H Soran","year":"2017","unstructured":"H. Soran, R. Dent, P. Durrington, Evidence-based goals in LDL-C reduction. Clin. Res. Cardiol. 106(4), 237\u2013248 (2017)","journal-title":"Clin. Res. Cardiol."},{"issue":"15","key":"2472_CR3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","volume":"97","author":"West of Scotland Coronary Prevention Study Group","year":"1998","unstructured":"West of Scotland Coronary Prevention Study Group, Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97(15), 1440\u20131445 (1998)","journal-title":"Circulation"},{"issue":"15","key":"2472_CR4","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","volume":"97","author":"FM Sacks","year":"1998","unstructured":"F.M. Sacks, L.A. Moy\u00e9, B.R. Davis et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 97(15), 1446\u20131452 (1998)","journal-title":"Circulation"},{"key":"2472_CR5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-90-481-8622-8_7","volume":"51","author":"S Lund-katz","year":"2010","unstructured":"S. Lund-katz, M.C. Phillips, High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell. Biochem. 51, 183\u2013227 (2010)","journal-title":"Subcell. Biochem."},{"issue":"12","key":"2472_CR6","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","volume":"97","author":"S Zhong","year":"1996","unstructured":"S. Zhong, D.S. Sharp, J.S. Grove et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Investig. 97(12), 2917\u20132923 (1996)","journal-title":"J. Clin. Investig."},{"key":"2472_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1874091X01206010078","volume":"6","author":"E Eren","year":"2012","unstructured":"E. Eren, N. Yilmaz, O. Aydin, High density lipoprotein and it\u2019s dysfunction. Open Biochem. J. 6, 78\u201393 (2012)","journal-title":"Open Biochem. J."},{"issue":"5519","key":"2472_CR8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"E.S. Istvan, J. Deisenhofer, Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292(5519), 1160\u20131164 (2001)","journal-title":"Science"},{"issue":"1","key":"2472_CR9","first-page":"41","volume":"61","author":"JE Feliciano-Alfonso","year":"2013","unstructured":"J.E. Feliciano-Alfonso, Rosuvastatin: role in cardiovascular high-risk patient. Rev. Fac. Med. 61(1), 41\u201351 (2013)","journal-title":"Rev. Fac. Med."},{"issue":"2","key":"2472_CR10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.atherosclerosis.2007.07.007","volume":"197","author":"D Sviridov","year":"2008","unstructured":"D. Sviridov, A. Hoang, E. Ooi et al. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 197(2), 732\u2013739 (2008)","journal-title":"Atherosclerosis"},{"issue":"6","key":"2472_CR11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1474651410388057","volume":"10","author":"PRJ Ames","year":"2010","unstructured":"P.R.J. Ames, A. Ortiz-Cadenas, I. Garcia De La Torre, A et al. Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein\/beta2-glycoprotein I complex concentration in type 2 diabetes. Br. J. Diabetes Vasc. Dis. 10(6), 292\u2013299 (2010)","journal-title":"Br. J. Diabetes Vasc. Dis."},{"issue":"2","key":"2472_CR12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.amjcard.2013.08.043","volume":"113","author":"H Takagi","year":"2014","unstructured":"H. Takagi, T. Umemoto; ALICE group, A meta-analysis of randomised head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoproteins profiles. Am. J. Cardiol. 113(2), 292\u2013301 (2014)","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"2472_CR13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1194\/jlr.P800040-JLR200","volume":"50","author":"B Verges","year":"2009","unstructured":"B. Verges, E. Florentin, S. Baillot-Rudoni et al. Rosuvastatin 20 mg restores normal HDL-apo A-I kinetics in type 2 diabetes. J. Lipid Res. 50(6), 1209\u20131215 (2009)","journal-title":"J. Lipid Res."},{"issue":"12","key":"2472_CR14","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1210\/jcem.82.12.4472","volume":"82","author":"RH Knopp","year":"1997","unstructured":"R.H. Knopp, X. Zhu, Multiple beneficial effects of estrogen on lipoprotein metabolism. J. Clin. Endocrinol. Metab. 82(12), 3952\u20133964 (1997)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2472_CR15","doi-asserted-by":"crossref","first-page":"1314864","DOI":"10.1155\/2017\/1314864","volume":"2017","author":"K Griffiths","year":"2017","unstructured":"K. Griffiths, A. Pazderska, M. Ahmed et al. Type 2 diabetes in young females results in increased serum amyloid a and changes to features of high density lipoproteins in both HDL2 and HDL3. J. Diabetes Res. 2017, 1314864 (2017)","journal-title":"J. Diabetes Res."},{"issue":"4","key":"2472_CR16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/gme.0b013e3181f6480e","volume":"18","author":"GA Woodard","year":"2011","unstructured":"G.A. Woodard, M.M. Brooks, E. Barinas-Mitchell et al. Lipids, menopause, and early atherosclerosis in Study of Women\u2019s Health Across the Nation Heart Women. Menopause 18(4), 376\u2013384 (2011)","journal-title":"Menopause"},{"key":"2472_CR17","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes Sec. 2. In Standards of medical care in diabetes\u20142016. Diabetes Care. 39(Suppl. 1), S13\u2013S22 (2016)","DOI":"10.2337\/dc16-S005"},{"issue":"3","key":"2472_CR18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12291-012-0194-y","volume":"27","author":"AM Rao","year":"2012","unstructured":"A.M. Rao, R. Apoorva, U. Anand, C.V. Anand, G. Venu, Effect of hemodialysis on plasma myeloperoxidase activity in end stage renal disease patients. Indian J. Clin. Biochem. 27(3), 253\u2013258 (2012)","journal-title":"Indian J. Clin. Biochem."},{"issue":"1","key":"2472_CR19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"D.J. Gordon, J.L. Probstfield, R.J. Garrison et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8\u201315 (1989)","journal-title":"Circulation"},{"issue":"2","key":"2472_CR20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"A.V. Khera, M. Cuchel, M. de la Llera-Moya et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364(2), 127\u2013135 (2011)","journal-title":"N. Engl. J. Med"},{"issue":"13","key":"2472_CR21","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1073\/pnas.80.13.4124","volume":"80","author":"DW Bilheimer","year":"1983","unstructured":"D.W. Bilheimer, S.M. Grundy, M.S. Brown, J.L. Goldstein, Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA 80(13), 4124\u20134128 (1983)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"2472_CR22","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1253\/circj.CJ-17-0411","volume":"82","author":"KY Jung","year":"2018","unstructured":"K.Y. Jung, K.M. Kim, S.K. Han et al. Effect of rosuvastatin on cholesterol efflux capacity and endothelial function in type 2 diabetes mellitus and dyslipidemia. Circ. J. 82(5), 1387\u20131395 (2018)","journal-title":"Circ. J."},{"issue":"4","key":"2472_CR23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jicc.2015.07.007","volume":"5","author":"CP Shah","year":"2015","unstructured":"C.P. Shah, D.K. Kumbla, A. Moorthy et al. A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). J. Indian Coll. Cardiol. 5(4), 282\u2013290 (2015)","journal-title":"J. Indian Coll. Cardiol."},{"issue":"1","key":"2472_CR24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","volume":"105","author":"SJ Nicholls","year":"2010","unstructured":"S.J. Nicholls, G. Brandrup-wognsen, M. Palmer et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol. 105(1), 69\u201376 (2010)","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"2472_CR25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/aps.2010.169","volume":"32","author":"J Yang","year":"2011","unstructured":"J. Yang, L.J. Li, K. Wang et al. Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients. Acta Pharmacol. Sin. 32(1), 116\u2013125 (2011)","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"2472_CR26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/eci.12226","volume":"44","author":"M Triolo","year":"2014","unstructured":"M. Triolo, W. Annema, J.F. Deboer et al. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur. J. Clin. Investig. 44(3), 240\u2013248 (2014)","journal-title":"Eur. J. Clin. Investig."},{"issue":"9","key":"2472_CR27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.5551\/jat.17210","volume":"20","author":"M Miyamoto-Sasaki","year":"2013","unstructured":"M. Miyamoto-Sasaki, T. Yasuda, T. Monguchi et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J. Atheroscler. Thromb. 20(9), 708\u2013716 (2013)","journal-title":"J. Atheroscler. Thromb."},{"issue":"1","key":"2472_CR28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacl.2017.10.011","volume":"12","author":"H Soran","year":"2018","unstructured":"H. Soran, Y. Liu, S. Adam et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. J. Clin. Lipidol. 12(1), 44\u201355 (2018)","journal-title":"J. Clin. Lipidol."},{"issue":"6","key":"2472_CR29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000082510","volume":"24","author":"ND Vaziri","year":"2004","unstructured":"N.D. Vaziri, K. Liang, Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome. Am. J. Nephrol. 24(6), 606\u2013613 (2004)","journal-title":"Am. J. Nephrol."},{"issue":"10","key":"2472_CR30","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1161\/ATVBAHA.114.303715","volume":"34","author":"T Shimizu","year":"2014","unstructured":"T. Shimizu, S. Miura, H. Tanigawa et al. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler. Thromb. Vasc. Biol. 34(10), 2246\u20132253 (2014)","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"2472_CR31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/diab.44.4.460","volume":"44","author":"D Bhatnagar","year":"1995","unstructured":"D. Bhatnagar, P.N. Durrington, S. Kumar, M.I. Mackness, J. Dean, A.J. Boulton, Effect of treatment with a hydroxy methyl glutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 44(4), 460\u2013465 (1995)","journal-title":"Diabetes"},{"issue":"2","key":"2472_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.atherosclerosis.2014.12.006","volume":"238","author":"L Masana","year":"2015","unstructured":"L. Masana, A. Cabr\u00e9, M. Heras et al. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis 238(2), 213\u2013219 (2015)","journal-title":"Atherosclerosis"},{"issue":"21","key":"2472_CR33","doi-asserted-by":"crossref","first-page":"11448","DOI":"10.1073\/pnas.93.21.11448","volume":"93","author":"JM Hoeg","year":"1996","unstructured":"J.M. Hoeg, S. Santamarina-Fojo, A.M. Berard et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. USA 93(21), 11448\u201311453 (1996)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"2472_CR34","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2008-1213","volume":"93","author":"RP Dullaart","year":"2008","unstructured":"R.P. Dullaart, F. Perton, W.J. Sluiter, R. de Vries, A. van Tol, Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J. Clin. Endocrinol. Metab. 93(12), 4860\u20134866 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2472_CR35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1006\/bbrc.1999.0690","volume":"258","author":"AB Kosek","year":"1999","unstructured":"A.B. Kosek, D. Durbin, A. Jonas, Binding affinity and reactivity of lecithin cholesterol acyltransferase with native lipoproteins. Biochem. Biophys. Res. Commun. 258(3), 548\u2013551 (1999)","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2472_CR36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbacli.2015.01.005","volume":"3","author":"A Hafiane","year":"2015","unstructured":"A. Hafiane, J. Genest, High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 3, 175\u2013188 (2015)","journal-title":"BBA Clin."},{"issue":"5","key":"2472_CR37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jdiacomp.2009.04.001","volume":"24","author":"AA Abdin","year":"2010","unstructured":"A.A. Abdin, M.A. Hassanien, E.A. Ibrahim, S.A. El-Noeman, Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. J. Diabetes Complicat. 24(5), 325\u2013333 (2010)","journal-title":"J. Diabetes Complicat."},{"issue":"Pt 3","key":"2472_CR38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1042\/bj3140739","volume":"314","author":"J Christison","year":"1996","unstructured":"J. Christison, A. Karjalainen, J. Brauman, F. Bygrave, R. Stocker, Rapid reduction and removal of HDL-but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem. J. 314(Pt 3), 739\u2013742 (1996)","journal-title":"Biochem. J."},{"key":"2472_CR39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1476-511X-12-137","volume":"12","author":"K Torimoto","year":"2013","unstructured":"K. Torimoto, Y. Okada, H. Mori et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 12, 137 (2013)","journal-title":"Lipids Health Dis."},{"issue":"6","key":"2472_CR40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5551\/jat.2956","volume":"17","author":"E Mandosi","year":"2010","unstructured":"E. Mandosi, M. Fallarino, A. Gatti et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNF alpha levels in type 2 diabetes. J. Atheroscler. Thromb. 17(6), 539\u2013545 (2010)","journal-title":"J. Atheroscler. Thromb."},{"issue":"2","key":"2472_CR41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.metabol.2015.10.012","volume":"65","author":"L Wei","year":"2016","unstructured":"L. Wei, M. Yamamoto, M. Harada, M. Otsuki, Treatment with atorvastatin attenuates progression of insulin resistance and pancreatic fibrosis in the Otsuka Long-Evans Tokushima fatty rats. Metab. Clin. Exp. 65(2), 41\u201353 (2016)","journal-title":"Metab. Clin. Exp."},{"key":"2472_CR42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12325-010-0098-2","volume":"28","author":"K Yanagi","year":"2011","unstructured":"K. Yanagi, T. Monden, S. Ikeda et al. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Adv. Ther. 28, 160\u2013171 (2011)","journal-title":"Adv. Ther."},{"issue":"1","key":"2472_CR43","first-page":"332","volume":"17","author":"G Ma","year":"2019","unstructured":"G. Ma, S. Bi, Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Exp. Ther. Med. 17(1), 332\u2013336 (2019)","journal-title":"Exp. Ther. Med."},{"issue":"12","key":"2472_CR44","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.bcp.2013.04.009","volume":"85","author":"K Wu","year":"2013","unstructured":"K. Wu, S. Tian, H. Zhou, Y. Wu, Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Biochem. Pharmacol. 85(12), 1753\u20131760 (2013)","journal-title":"Biochem. Pharmacol."},{"issue":"24","key":"2472_CR45","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehl277","volume":"27","author":"A Link","year":"2006","unstructured":"A. Link, T. Ayadhi, M. B\u00f6hm, G. Nickenig, Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur. Heart J. 27(24), 2945\u20132955 (2006)","journal-title":"Eur. Heart J."},{"issue":"3","key":"2472_CR46","first-page":"379","volume":"140","author":"A Mohan","year":"2014","unstructured":"A. Mohan, S. Sada, B.S. Kumar et al. Subclinical atherosclerosis in patients with rheumatoid arthritis by utilizing carotid intima-media thickness as a surrogate marker. Indian J. Med. Res. 140(3), 379\u2013386 (2014)","journal-title":"Indian J. Med. Res."},{"issue":"1","key":"2472_CR47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.atherosclerosis.2010.10.045","volume":"214","author":"Society of Atherosclerosis Imaging and Prevention developed in collaboration with the International Atherosclerosis Society","year":"2011","unstructured":"Society of Atherosclerosis Imaging and Prevention developed in collaboration with the International Atherosclerosis Society, Appropriate use criteria for carotid intima media thickness testing. Atherosclerosis 214(1), 43\u201346 (2011)","journal-title":"Atherosclerosis"},{"issue":"25","key":"2472_CR48","first-page":"e584","volume":"122","author":"P Greenland","year":"2010","unstructured":"P. Greenland, J.S. Alpert, G.A. Beller et al. 2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 122(25), e584\u2013e636 (2010)","journal-title":"Circulation"},{"issue":"25","key":"2472_CR49","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/CIRCULATIONAHA.116.025678","volume":"135","author":"AV Khera","year":"2017","unstructured":"A.V. Khera, O.V. Demler, S.J. Adelman et al. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation 135(25), 2494\u20132504 (2017)","journal-title":"Circulation"},{"issue":"9","key":"2472_CR50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.numecd.2008.12.005","volume":"19","author":"FR Jornayvaz","year":"2009","unstructured":"F.R. Jornayvaz, M.C. Brulhart-meynet, R.W. James, Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr. Metab. Cardiovasc. Dis. 19(9), 613\u2013619 (2009)","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"7","key":"2472_CR51","first-page":"359","volume":"71","author":"PG Scheffer","year":"2013","unstructured":"P.G. Scheffer, R.K. Schindhelm, V.M. vanVerschuer et al. No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease. Neth. J. Med. 71(7), 359\u2013365 (2013)","journal-title":"Neth. J. Med."},{"issue":"12","key":"2472_CR52","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","volume":"297","author":"JR Crouse","year":"2007","unstructured":"J.R. Crouse, J.S. Raichlen, W.A. Riley, METEOR Study Group et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297(12), 1344\u20131353 (2007)","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1007\/s12020-020-02517-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000}}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02472-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T19:33:53Z","timestamp":1630956833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02472-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2472"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02472-5","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"4 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee and registered with the Clinical Trials Registry of India (CTRI\/2017\/09\/009695).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}